LAC-Shield™, Morinaga Milk's New "Immunogenics" Ingredient, Offers Manufacturers Clinically Tested Immune Benefits and Shelf Stability
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced that its recently launched “Immunogenics” ingredient LAC-Shield will now be marketed overseas. The product, a heat-killed strain of beneficial Lactobacillus bacteria (Lactobacillus paracasei MCC1849), has been clinically shown to have immune-enhancing benefits. Yet because it has been pasteurized, LAC-Shield does not pose the stability issues of traditional probiotics.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170906005110/en/
(Fig. 1) LAC-Shield showed the highest ability to stimulate immune function of all strains tested (Graphic: Business Wire)
Probiotics are widely consumed in various foods and dietary supplements by people worldwide for a range of health benefits, including their positive effect on immune function. However, there are application challenges when formulating with probiotics, since live bacteria often do not survive at high temperatures or under high water-activity environments.
“LAC-Shield is unique because it can be added to a wide range of foods and beverages in which conventional probiotics can’t survive. This high level of versatility has helped us achieve great success in the Japanese market,” Dr. Fumiaki Abe, General Manager of Morinaga’s Food Ingredients & Technology Institute, emphasized. More than 150 food companies are currently using LAC-Shield for various food and beverage applications in Japan.
LAC-Shield Has High Potential to Stimulate Immune Function
It is well established that the gut microbiome interacts with the mucosal immune system, and scientists now believe that microbes have a much greater impact on immune function than previously realized, whether the bacteria is alive or dead. Taking this research into account, Morinaga Milk screened a number of strains of helpful bacteria to select the one with the highest potential to enhance the immune system in its development of “Immunogenics” LAC-Shield. The company selected the strain Lactobacillus paracasei MCC1849 from its collection of thousands of cultures because it showed an immune-stimulating effect even when pasteurized, as measured by its ability to induce the production of IL-12 (a cytokine that activates cellular immunity) by immune cells (Fig. 1).
LAC-Shield Lowers Risk of Common Cold
A new human clinical study collaborating with Professor Koshiro Miura and Associate Professor Junko Kondo of Kyushu Women’s University examined the effect of LAC-Shield on the common cold in 241 healthy women over age 18. Participants were randomized to receive either LAC-Shield (10 billion or 30 billion cells) or placebo powder every day for 12 weeks. Subjective symptoms of the common cold — such as cough, sore throat, sneezing, nasal congestion, headache, malaise, and fever — were recorded every day for 12 weeks.
At the end of the study, among subjects who had caught a cold within the past year, LAC-Shield (10 billion cells) significantly reduced the incidence of the common cold, the total number of days symptoms lasted, and symptom severity score. These results were presented at the International Union of Microbiological Societies conference held in Singapore July 17-21, 2017.
LAC-Shield May Help Enhance the Effectiveness of the Flu Shot
Another human clinical study on LAC-Shield was conducted by Dr. Michio Murayama of Tanashi Hospital in a population of 42 elderly subjects living in nursing homes.1 Participants were randomized to receive either LAC-Shield (10 billion cells) or placebo by jelly every day for 6 weeks during the winter. They also received an influenza vaccination containing three viral antigens (A/H1N1, A/H2N3 and B) in the third week of the study. Researchers compared the antigen titer to vaccine antigen at the beginning and end of the study.
Antibody response to vaccination typically declines with age, becoming especially weak in the very elderly and rendering them vulnerable to infectious disease, even when vaccinated. However, supplementation with LAC-Shield improved the impaired antibody response to the A/H1N1 and B antigens in the subgroup of those over 85 years old. Hence, LAC-Shield increased the efficacy of the influenza vaccination by enhancing immune response.
Generally probiotics is thought to have both direct and indirect roles on immune system; the direct effect of bacteria itself on gut immunity and the indirect effect by beneficial metabolites such as short-chain fatty acids produced in the gut. “Pasteurized bacteria can be expected only the direct effect, however, we see massive potential in LAC-Shield for its immune enhancing effect and application diversity,” stated Dr. Abe. “We are very excited about the high level of interest we have already received in overseas markets. Now we will accelerate our global sales of this unique product, which can be used in a wide variety of food and beverage applications.”
Please visit our booth at Exhibition Hall 104 D07 at Fi Asia, Bangkok (September 13-15, 2017)
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan. Morinaga started research on bifidobacteria in the 1960s, inspired by the fact that bifidobacteria are the predominant bacteria residing in the intestines of breast-fed infants. In 1969, Morinaga isolated its flagship strain Bifidobacterium longum BB536 from an infant. Currently, Morinaga is launching a unique probiotics-derived “Immunogenics” product, which expands the number of possible applications for probiotics. Morinaga is celebrating its 100th anniversary in 2017.
1. M. Maruyama et al., International Journal of Food Sciences and Nutrition, DOI: 10.3109/09637486.2015.1126564 (2015)
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy19.9.2017 19:00 | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced that the European Commission has approved Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of Xermelo® (telotristat ethyl) in the above indication in all 28 member states of the European Union, Norway and Iceland. David Meek, Chief Executive Officer, Ipsen stated: “We are delighted to provide patients suffering from inadequately controlled carcinoid syndrome with a new treatment option in combination with a somatostatin analogue that demonstrates both efficacy and safety in particularly improving diarrhea, a most debilitating symptom. Xe
6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England19.9.2017 18:00 | Tiedote
The Patient Safety Movement Foundation (PSMF) announces that the 6th Annual World Patient Safety, Science & Technology Summit will take place in London on February 23-25, 2018. Rt. Hon. Jeremy Hunt MP, the Secretary of State for Health from England’s Department of Health, invited PSMF to hold its 6th annual Summit in London during his speech at the Summit in February of this year. This is the first time the Summit will be held outside of the United States. Over the years, the PSMF has taken an increasingly international scope to reach zero preventable patient deaths by 2020. They currently have over 30 Regional Chapters around the world and partnerships with global organizations such as the World Federation of Societies of Anaesthesiologists (WFSA), European Society of Anaesthesiology (ESA), Global Sepsis Alliance (GSA), the Taiwan Patient Safety Culture Club, Sistema Españo
Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference19.9.2017 17:50 | Tiedote
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its cystic fibrosis (CF) research and development program will be presented at the annual North American Cystic Fibrosis Conference (NACFC) in Indianapolis, November 2 to 4, 2017. Previously announced data from the Phase 3 EVOLVE and EXPAND studies of the investigational tezacaftor/ivacaftor combination in people with CF ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will be presented for the first time. Additionally, data from the Phase 3 extension study of ORKAMBI® (lumacaftor/ivacaftor) in children with CF ages 6 to 11 who have two copies of the F508del mutation and real-world KALYDECO® (ivacaftor) data will be presented. The company also submitted an abstract for the late-breaking poster session with previously announced Phase 1
Biker Summer 2017 campaign: Last Chance to Win Great Prizes from Moto-tyres.co.uk19.9.2017 16:57 | Tiedote
Moto-tyres.co.uk wants to know: For the fifth year in a row, the online motorbike shop is asking bikers from ten European countries about their Biker Summer 2017 travel plans, favourite destinations and longest tours. For survey participants, Moto-tyres.co.uk and its sister shops in other European countries are raffling prizes to get every biker’s heart beating faster, including vouchers for new motorbike tyres, a GARMIN motorbike GPS navigation system, and a GoPro camera with helmet attachment. For more information and a link to the survey, go to: www.moto-tyres.co.uk/promotion-biker-summer-2017.html. The Biker Summer 2017 campaign is running until 30th September 2017 – so you still have time to join in and win top-quality equipment for your next bike tour. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170919006105/en/
Andersen Global Expands into Uruguay19.9.2017 16:30 | Tiedote
Andersen Global announces its expansion into Uruguay through a Collaboration Agreement with Fischer & Schickendantz, one of the country’s leading law firms. The addition of Fischer & Schickendantz continues Andersen Global’s expansion and robust presence within the Latin American region. The team is led by Managing Partner, Juan Federico Fischer. “The addition of Juan Federico and the individuals at Fischer & Schickendantz bring a new depth to our team and our business development efforts in South America, while allowing us to deliver additional services in the region,” said Andersen Tax CEO, Mark Vorsatz. “Uruguay is the next major step in our firm’s growth and is an excellent complement for Andersen Global. The ability to provide a full scope of services in Uruguay offers significant advantages, especially given their large cross border client base and Uruguay’s increase
Horizon Petroleum Enters into Definitive Agreements to Acquire Concessions in Poland19.9.2017 16:05 | Tiedote
Horizon Petroleum Ltd. (the “Company” or “Horizon”) (TSXV:HPL) is pleased to report that further to its press releases dated June 23, 2017, and July 26, 2017, it has entered into a series of definitive agreements (the “Agreements”) with Dublin-based San Leon Energy plc (“SLE”) regarding the purchase from wholly-owned subsidiaries of SLE and other SLE-controlled entities, of 100% interests in 2 oil & gas concessions in the Republic of Poland known as Cieszyn and Bielsko-Biala (the “Primary Concessions”), plus 100% working interests in 2 additional oil & gas concessions in Poland known as Prusice and Kotlarka, and another concession which is under application (together the “Secondary Concessions”). These concessions cover 3,030km2 and lie within the prolific Rotliegendes Basin and Carpathian Foldbelt, where Horizon intends to target undeveloped conventional natural gas discoveries. Gas infr
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme